Table 3 Univariate and multivariable logistic regression analyses of different underlying factors for the development of pneumocystis infection.

From: Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

Risk factor

Simple regression

Multiple regression

HR

95% CI

P value

HR

95% CI

P value

Rituximab

2.33

(1.75–3.09)

<0.0001

2.47

(1.84–3.3)

<0.0001

Gender (Male)

1.41

(1.11–1.8)

0.0057

1.51

(1.18–1.94)

0.001

Age (y)

Ā Ā 45–60 vs. ≤ 45

1.11

(0.8–1.52)

0.544

0.95

(0.69–1.32)

0.7687

Ā Ā 60–70 vs. ≤45

1.27

(0.9–1.79)

0.1726

1.07

(0.75–1.54)

0.709

Ā Ā >70 vs.≤45

0.98

(0.69–1.37)

0.8867

0.83

(0.57–1.22)

0.3412

COPD

0.87

(0.67–1.12)

0.2786

0.9

(0.69–1.18)

0.4413

RD

0.97

(0.73–1.3)

0.8535

1.07

(0.79–1.45)

0.6751

DM

0.88

(0.65–1.2)

0.4214

0.87

(0.63–1.19)

0.3796

CKD

0.64

(0.37–1.12)

0.1159

0.65

(0.37–1.15)

0.1357

  1. COPD = Chronic pulmonary disease, RD = Rheumatologic disease, DM = Diabetes mellitus, CKD = Chronic kidney disease.